200 related articles for article (PubMed ID: 27769070)
1. Characterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressing MYCN in hGFAP-positive cells.
Fielitz K; Althoff K; De Preter K; Nonnekens J; Ohli J; Elges S; Hartmann W; Klöppel G; Knösel T; Schulte M; Klein-Hitpass L; Beisser D; Reis H; Eyking A; Cario E; Schulte JH; Schramm A; Schüller U
Oncotarget; 2016 Nov; 7(46):74415-74426. PubMed ID: 27769070
[TBL] [Abstract][Full Text] [Related]
2. MYCN-mediated murine cancer models.
Althoff K; Schramm A
Aging (Albany NY); 2017 Apr; 9(4):1084-1085. PubMed ID: 28377536
[No Abstract] [Full Text] [Related]
3. Progranulin Stimulates Proliferation of Mouse Pancreatic Islet Cells and Is Overexpressed in the Endocrine Pancreatic Tissue of an MEN1 Mouse Model.
Barbu A; Lejonklou MH; Skogseid B
Pancreas; 2016 Apr; 45(4):533-40. PubMed ID: 26495792
[TBL] [Abstract][Full Text] [Related]
4. Multiple glucagon-producing pancreatic neuroendocrine tumors in a horse (Equus caballus).
Herbach N; Nagel L; Zwick T; Hermanns W
Vet Pathol; 2014 May; 51(3):607-11. PubMed ID: 23774746
[TBL] [Abstract][Full Text] [Related]
5. A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies.
Althoff K; Beckers A; Bell E; Nortmeyer M; Thor T; Sprüssel A; Lindner S; De Preter K; Florin A; Heukamp LC; Klein-Hitpass L; Astrahantseff K; Kumps C; Speleman F; Eggert A; Westermann F; Schramm A; Schulte JH
Oncogene; 2015 Jun; 34(26):3357-68. PubMed ID: 25174395
[TBL] [Abstract][Full Text] [Related]
6. Glucagonomas of transgenic mice express a wide range of general neuroendocrine markers and bioactive peptides.
Rindi G; Efrat S; Ghatei MA; Bloom SR; Solcia E; Polak JM
Virchows Arch A Pathol Anat Histopathol; 1991; 419(2):115-29. PubMed ID: 1678563
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic Neuroendocrine Tumors in Mice Deficient in Proglucagon-Derived Peptides.
Takano Y; Kasai K; Takagishi Y; Kikumori T; Imai T; Murata Y; Hayashi Y
PLoS One; 2015; 10(7):e0133812. PubMed ID: 26192435
[TBL] [Abstract][Full Text] [Related]
8. Alpha cell-specific Men1 ablation triggers the transdifferentiation of glucagon-expressing cells and insulinoma development.
Lu J; Herrera PL; Carreira C; Bonnavion R; Seigne C; Calender A; Bertolino P; Zhang CX
Gastroenterology; 2010 May; 138(5):1954-65. PubMed ID: 20138042
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of neuroendocrine tumors in transgenic mice.
Rindi G
Digestion; 1994; 55 Suppl 3():24-30. PubMed ID: 7698534
[TBL] [Abstract][Full Text] [Related]
10. MYCN Transforms Prostate Epithelium to Neuroendocrine Prostate Cancer.
Cancer Discov; 2016 Jun; 6(6):OF19. PubMed ID: 27080339
[TBL] [Abstract][Full Text] [Related]
11. MYCN induces neuroblastoma in primary neural crest cells.
Olsen RR; Otero JH; García-López J; Wallace K; Finkelstein D; Rehg JE; Yin Z; Wang YD; Freeman KW
Oncogene; 2017 Aug; 36(35):5075-5082. PubMed ID: 28459463
[TBL] [Abstract][Full Text] [Related]
12. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer.
Zhang W; Liu B; Wu W; Li L; Broom BM; Basourakos SP; Korentzelos D; Luan Y; Wang J; Yang G; Park S; Azad AK; Cao X; Kim J; Corn PG; Logothetis CJ; Aparicio AM; Chinnaiyan AM; Navone N; Troncoso P; Thompson TC
Clin Cancer Res; 2018 Feb; 24(3):696-707. PubMed ID: 29138344
[No Abstract] [Full Text] [Related]
13. Serine protease inhibitor 8 is a novel immunohistochemical marker for neuroendocrine tumors of the pancreas.
de Koning PJ; Bovenschen N; Broekhuizen R; Lips CJ; Kummer JA
Pancreas; 2009 May; 38(4):461-7. PubMed ID: 19188865
[TBL] [Abstract][Full Text] [Related]
14. A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics.
Sadanandam A; Wullschleger S; Lyssiotis CA; Grötzinger C; Barbi S; Bersani S; Körner J; Wafy I; Mafficini A; Lawlor RT; Simbolo M; Asara JM; Bläker H; Cantley LC; Wiedenmann B; Scarpa A; Hanahan D
Cancer Discov; 2015 Dec; 5(12):1296-313. PubMed ID: 26446169
[TBL] [Abstract][Full Text] [Related]
15. Targeted expression of human MYCN selectively causes pancreatic neuroendocrine tumors in transgenic zebrafish.
Yang HW; Kutok JL; Lee NH; Piao HY; Fletcher CD; Kanki JP; Look AT
Cancer Res; 2004 Oct; 64(20):7256-62. PubMed ID: 15492244
[TBL] [Abstract][Full Text] [Related]
16. Mouse models of pediatric high-grade gliomas with MYCN amplification reveal intratumoral heterogeneity and lineage signatures.
Schoof M; Godbole S; Albert TK; Dottermusch M; Walter C; Ballast A; Qin N; Olivera MB; Göbel C; Neyazi S; Holdhof D; Kresbach C; Peter LS; Epplen GD; Thaden V; Spohn M; Blattner-Johnson M; Modemann F; Mynarek M; Rutkowski S; Sill M; Varghese J; Afflerbach AK; Eckhardt A; Münter D; Verma A; Struve N; Jones DTW; Remke M; Neumann JE; Kerl K; Schüller U
Nat Commun; 2023 Nov; 14(1):7717. PubMed ID: 38001143
[TBL] [Abstract][Full Text] [Related]
17. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
Dardenne E; Beltran H; Benelli M; Gayvert K; Berger A; Puca L; Cyrta J; Sboner A; Noorzad Z; MacDonald T; Cheung C; Yuen KS; Gao D; Chen Y; Eilers M; Mosquera JM; Robinson BD; Elemento O; Rubin MA; Demichelis F; Rickman DS
Cancer Cell; 2016 Oct; 30(4):563-577. PubMed ID: 27728805
[TBL] [Abstract][Full Text] [Related]
18. GFAP-Cre-mediated transgenic activation of Bmi1 results in pituitary tumors.
Westerman BA; Blom M; Tanger E; van der Valk M; Song JY; van Santen M; Gadiot J; Cornelissen-Steijger P; Zevenhoven J; Prosser HM; Uren A; Aronica E; van Lohuizen M
PLoS One; 2012; 7(5):e35943. PubMed ID: 22574128
[TBL] [Abstract][Full Text] [Related]
19. Mice transgenic for a vasopressin-SV40 hybrid oncogene develop tumors of the endocrine pancreas and the anterior pituitary. A possible model for human multiple endocrine neoplasia type 1.
Murphy D; Bishop A; Rindi G; Murphy MN; Stamp GW; Hanson J; Polak JM; Hogan B
Am J Pathol; 1987 Dec; 129(3):552-66. PubMed ID: 2827490
[TBL] [Abstract][Full Text] [Related]
20. A mouse model of MYCN-driven retinoblastoma reveals MYCN-independent tumor reemergence.
Wu N; Jia D; Bates B; Basom R; Eberhart CG; MacPherson D
J Clin Invest; 2017 Mar; 127(3):888-898. PubMed ID: 28165337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
